诺华有望迎来美国上市的第一个生物类似物
核心提示:2014年1月6日讯/生物谷BIOON/--作为安进肿瘤生物药Neupogen的生物类似物,诺华Zarzio近日获得了FDA官员的推荐,同时该药也有望成为美国第一个上市的生物类似物。
2014年1月6日讯/生物谷BIOON/--作为安进肿瘤生物药Neupogen的生物类似物,诺华Zarzio近日获得了FDA官员的推荐,同时该药也有望成为美国第一个上市的生物类似物。
根据2010年颁布的患者保护与平价医疗法案,只要具有足够的价格优势,研发的生物类似物与原研药即使不百分百等同也可以获批。从2006年开始,欧洲的生物类似物就逐渐获批,而美国由于缺乏相关的规章制度,生物类似物市场发展仍相对滞后。
生物药在癌症和其他免疫疾病的治疗方面具有更好的安全性和有效性,然而这也导致了价格过高,不是每个患者都可以消费得起。目前全球销量前十的药品当中,六种是生物技术药物。
由于生物技术药是从活细胞中研发获取,不能保证与原研药完全相同。价格低廉的仿制药是从不同细胞系中制取的,因此监管部门需要出台一系列制度保证仿制药的安全性和有效性在最大程度上接近原研药。
FDA报道,在审批的过程中,没有发现诺华的生物类似物与原研药之间具有“有意义的临床差异”,简言之就是二者的安全性和疗效相同。2014年12月,诺华宣布在后期试验中,类似物与原研药具有相似的安全性和疗效。
Neupogen是一种注射药物,用来预防化疗后患者的感染,该药物在2014年为安进贡献了12亿美元的销量,而诺华将会以Zarzio作为该仿制药的商品名,由诺华旗下仿制药单元Sandoz生产,销往全球40个国家。
FDA的评审认为,该类似物应当与Neupogen保持一致,获批治疗所有5项适应症。该建议会在1月7号讨论,并得出最终决定。
根据Express Scripts 估计,生物类似物降低20—30%的售价(相比于原研药),十年共能节约2500亿美元开支。(生物谷Bioon.com)
原文 Novartis’ Biosimilar Of Amgen’s Neupogen Gets FDA Staff Nod
Novartis AG (ADR) (NYSE:NVS) has received a recommendation by US Food and Drug Administration staff for the approval of its biosimilar drug, an imitation of Amgen, Inc.'s (NSADQ:AMGN) oncology biotech drug, Neupogen. The approval was based on the reviews from the staff that reported that the safety and efficacy profiles of the drug were similar to Neupogen.
Novartis’s imitation drug is the first biosimilar to be reviewed in the US. The FDA can now approve imitation drugs under the Patient Protection and Affordable Care Act 2010, according to which, biosimilars can be developed which are not exactly identical and are cheaper. Biosimilars have been getting approved in Europe since 2006, but the lack of a regulatory framework in the US was the reason the country lagged in the biotech drug imitation market.
Biotechs have better safety profiles and are more effective in cancer treatment and other immunological diseases resulting in highly expensive price tags which are not affordable to everyone. Out of the world’s 10 best-selling drugs today, six are biotech drugs.
Biotech drugs are developed from living cells and thus cannot be copied exactly. Since the cheaper imitations are made from different cell-lines, regulatory authorities have to develop studies to be conducted to ensure the safety of the imitations and assess their safety and efficacy.
The FDA reported that the staff reviewing the biosimilar from Novartis did not find any "clinically meaningful differences" between the original and the copy. In December 2014, Novartis announced top-line results from a late-stage study showing that the imitation had similar safety and efficacy profiles as those of the original drug.
Neupogen is an injectable drug and has been developed to prevent infections in cancer patients who are already receiving chemotherapy. The drug generated $1.2 billion in revenue for Amgen in 2014. Novartis sells imitations for Neupogen in over 40 countries under the brand name Zarzio, manufactured by its generic drug unit, Sandoz.
The FDA reviewers recommended that the biosimilar should get approval for all five indications for which the original drug has been approved. The recommendation report will be reviewed by FDA experts on January 7 to make a final decision about the approval.
Biosimilars are expected to cost 20% to 30% less and are expected to save $250 billion in 10 years from their introduction, as estimated by Express Scripts Holding Company
责任编辑:露儿
-
新版医保目录8月来袭 这四类药调入呼声最高
近日,国家医保局发布《2019年国家医保药品目录调整工作方案(征求意见稿)》(以下简称《意见稿》),明确2019年医保目录调整工作分为三个阶段,即1-3月准备阶段,4-5月评审阶段(确定备选名单、遴选专家投票、确定调入调出药品名单、谈判),2019年6月常规目录发布阶段,2019年6-7月谈判阶段,2019年8月发布谈判准入目录。...
-
央视曝光药师挂证乱象 药师挂证再迎整顿潮
央视3.15晚会曝光挂证乱象,某执业药师挂证平台已无法访问,药师挂证再迎整顿潮。...
-
地板价!广东药价全省联动
3月12日,广东省人民政府官网发布《关于印发广东省改革完善医疗卫生行业综合监管制度实施方案的通知》。...
-
大批医药代表工资下降?新机会来了
目前,似乎整个行业被悲观的情绪所笼罩:曾有资深的医药代表对赛柏蓝表示,现在“悲观”是大趋势:政策压力大导致的从业环境不理想,控费背景下完不成指标,所做的产品市场空间有限…… ...
-
金额公开!全国医院用药品种、科室、药企排名
金额公开!全国医院用药品种、科室、药企排名...
-
4+7未中选药品大降价!格列卫历史最低
海发通知,4+7未中选药品降价!格列卫(100mg*60片)降至7182元,创历史最低。...
-
刚刚!3个大品种说明书被改,儿童、孕妇禁用!
刚刚!3个大品种说明书被改,儿童、孕妇禁用!...
-
刚刚!这60个药,被暂停采购(附名单)
2月27日,江西省医药采购服务平台发布《关于调整二甲双胍等药品网上采购资格的通知》,有60个药被暂停挂网资格,涉及46家药企。...
-
4+7未中选高价药,提高自负比例
4+7最新文件,未中选高价药,提高自负比例,未中选药品梯度降价。...
-
药监不放假 加班查药店!5大重点需注意
这个春节,药监没放假,重点对药店执业药师在职在岗和处方药销售进行了检查。节后整治五重点,所有药店需注意。...
-
辅助用药,再迎致命打击
近日,业内流传一份由国家卫健委药政司起草的《关于征求开展药品使用监测和临床综合评价工作通知(征求意见稿)意见的函》(以下简称《意见稿》)。...
-
通过率仅14.1%!执业药师考试创7年最低
近日,国家药监局执业药师资格认证中心发布通知,公布2018年度国家执业药师资格考试合格标准和考试结果。...